Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids

Recent discovery and characterization of APOAV suggests a role in metabolism of triglyceride (TG)-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma TGs in normolipidemic samples. The aims of this study were to assess the effects of a polymorphism in A...

Full description

Saved in:
Bibliographic Details
Published in:Journal of lipid research 2003-06, Vol.44 (6), p.1167-1173
Main Authors: Aouizerat, Bradley E, Kulkarni, Medha, Heilbron, David, Drown, Donna, Raskin, Stephen, Pullinger, Clive R, Malloy, Mary J, Kane, John P
Format: Article
Language:English
Subjects:
Adult
Aged
Alleles
Apolipoprotein A-V
Apolipoproteins - genetics
Apolipoproteins A
Cardiovascular Diseases - blood
Cardiovascular Diseases - ethnology
Cardiovascular Diseases - genetics
dyslipidemia
Ethnic Groups
ethnicity
Female
Humans
Hyperlipidemias - genetics
Hyperlipoproteinemias - genetics
Hypolipoproteinemias - genetics
Linear Models
Lipid Metabolism
Lipids - blood
lipoprotein
Middle Aged
Polymorphism, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent discovery and characterization of APOAV suggests a role in metabolism of triglyceride (TG)-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma TGs in normolipidemic samples. The aims of this study were to assess the effects of a polymorphism in APOAV (T-1131C) in terms of its frequency among three dyslipidemic populations and a control population, differences of allele frequency across available ethnic groups, and associations with specific lipoprotein TG and cholesterol compartments. We found a striking elevation in the frequency of the rare allele in a Chinese population (P = 0.0002) compared with Hispanic and European populations. The rare allele of the polymorphism was associated with elevated plasma TG (P = 0.012), VLDL cholesterol (P = 0.0007), and VLDL TG (P = 0.012), LDL TG (P = 0.003), and HDL TG (P = 0.016). Linear regression models predict that possession of the rare allele elevates plasma TG by 21 mg/dl (P = 0.009) and VLDL cholesterol by 8 mg/dl (P = 0.0001), and reduces HDL cholesterol by 2 mg/dl (P = 0.017). The association of the polymorphism with altered lipoprotein profiles was observed in combined hyperlipidemia, hypoalphalipoproteinemia, and hyperalphalipoproteinemia, and in controls. These findings indicate that APOAV is an important determinant of plasma TG and lipoprotein cholesterol, and is potentially a risk factor for cardiovascular disease.
ISSN:0022-2275
DOI:10.1194/jlr.m200480-jlr200